| __timestamp | Merus N.V. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 1860000 |
| Thursday, January 1, 2015 | 839656 | 2963000 |
| Friday, January 1, 2016 | 4478145 | 6961000 |
| Sunday, January 1, 2017 | 16432324 | 11779000 |
| Monday, January 1, 2018 | 11890871 | 13697000 |
| Tuesday, January 1, 2019 | 34110000 | 15749000 |
| Wednesday, January 1, 2020 | 35781000 | 18638000 |
| Friday, January 1, 2021 | 40896000 | 27196000 |
| Saturday, January 1, 2022 | 52200000 | 31739000 |
| Sunday, January 1, 2023 | 59836000 | 33491000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational costs is crucial for success. Over the past decade, Merus N.V. and Protagonist Therapeutics, Inc. have demonstrated distinct strategies in handling their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merus N.V. saw a staggering 1,450% increase in SG&A expenses, peaking at nearly $60 million in 2023. In contrast, Protagonist Therapeutics, Inc. experienced a more moderate rise of 1,700%, reaching approximately $33 million in the same year.
This divergence highlights Merus N.V.'s aggressive expansion and investment in administrative capabilities, while Protagonist Therapeutics, Inc. maintains a more conservative approach. Understanding these trends offers valuable insights into each company's strategic priorities and operational efficiency. As the biotech landscape evolves, these financial strategies will play a pivotal role in shaping their future trajectories.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Protagonist Therapeutics, Inc.
Amgen Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Alkermes plc vs Merus N.V.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and Merus N.V.
Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: MorphoSys AG vs Merus N.V. Trends and Insights
Comparing SG&A Expenses: Vericel Corporation vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Merus N.V. or Amphastar Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc. or Agios Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Protagonist Therapeutics, Inc. vs Evotec SE: SG&A Expense Trends